Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.87 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.87 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.87 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.87 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.87 |
| ▸ | DRD2 | P14416 | 1/20 | 0.87 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.87 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.87 |
| ▸ | MAOA | P21397 | 1/20 | 0.87 |
| ▸ | DRD4 | P21917 | 1/20 | 0.87 |
| ▸ | MAOB | P27338 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | HRH1 | P35367 | 1/20 | 0.87 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23651660 | 0.95 | OPRM1 (0.87) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL916599 | 0.93 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL8804 | 0.93 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL28383546 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL22637301 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4324385 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4971300 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL18249370 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4321837 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4353786 | 0.92 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | INHERIS BIOPHARMA INC (US) | 2020-03-12 | — | — | US | disclosed |
| CN-105503889-B | Oligomer-opioid agonist conjugates | 尼克塔治疗公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10143690-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180296550-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2018-10-18 | — | — | US | disclosed |
| WO-2011011543-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| CN-100402084-C | Method for detection or quantitative determination of metabolite of fentanyl or metabolite of fentanyl analogues and kit | LANDAUKES LAB CO LTD (GB) | 2008-07-16 | — | — | CN | disclosed |
| EP-1312923-B1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LAB LTD (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-7109310-B2 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LABORATORIES, LTD. (IE) | 2006-09-19 | — | — | US | disclosed |
| US-20030170728-A1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LABORATORIES LIMITED | 2003-09-11 | — | — | US | disclosed |
| CN-1428607-A | Method for detection or quantitative determination of metabolite of fentanyl or metabolite of fentanyl analogues and kit | LANDAUKES LAB CO LTD (GB) | 2003-07-09 | — | — | CN | disclosed |
| EP-1312923-A2 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | Randox Laboratories Ltd. (GB) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10143690-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20030170728-A1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | OPRK1, KIT, OPRM1 | OPRM1 3/4885OPRD1 14/4885OPRK1 1/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20180296550-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.